Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer
Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer
A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The
 patients were randomly divided into the WLS-intervention group and the control group. The two
 groups of patients were given the most appropriate medication according to the specific
 conditions of the disease. Patients in the intervention group received additional oral
 administration of Weileshu, a probiotics product (Tongchuang Biotechnology).
Inclusion Criteria:

 -  At least 18 years of age, of any race or sex who are eligible to sign written consent
 and have undergone prior resection of histological evidence of colorectal cancer

 -  Hematologic function: ANC ≥ 1.5 x 10 /L, platelets ≥ 75 x 10 /L, and hemoglobin > 9
 g/dL Adequate liver function as measured by: total bilirubin ≤ 2.0 mg/dl, AST and ALT
 ≤ 5 ULN, albumin ≥ 2.5 g/dl Adequate renal function as measured by: creatinine ≤ 2.9
 mg/dl, > 50 ml/min calculated by the C-G equation Non-pregnant women of childbearing
 potential and fertile men are required to use effective contraception (negative
 pregnancy test for women of child-bearing age) ECOG status ≤ 1 at screening

 Exclusion Criteria:

 -